Literature DB >> 17242688

Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy.

Qi Zhang1, Guihua Chen, Xinyuan Liu, Qijun Qian.   

Abstract

Antibodies as therapeutic agents are mostly used in oncology, as illustrated by their applications in lymphoma, breast cancer or colorectal cancer. This review provides a brief historical sketch of the development of monoclonal antibodies for cancer treatment and summarizes the most significant clinical data for the best-established reagents to date. It also discusses strategies to improve the anti-tumor efficacy of antibody therapy, including antibody gene therapy and exploitation of bone marrow derived primary mesenchymal stem cells as the antibody gene transporter.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17242688     DOI: 10.1038/sj.cr.7310143

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  19 in total

1.  A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.

Authors:  Gennaro Riccio; Chiara D'Avino; Ronald T Raines; Claudia De Lorenzo
Journal:  Protein Eng Des Sel       Date:  2012-12-11       Impact factor: 1.650

Review 2.  A review on various targeted anticancer therapies.

Authors:  Junjie Li; Feng Chen; Marlein Miranda Cona; Yuanbo Feng; Uwe Himmelreich; Raymond Oyen; Alfons Verbruggen; Yicheng Ni
Journal:  Target Oncol       Date:  2012-02-15       Impact factor: 4.493

Review 3.  Recent trends in targeted anticancer prodrug and conjugate design.

Authors:  Yashveer Singh; Matthew Palombo; Patrick J Sinko
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

4.  Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.

Authors:  Chiara D'Avino; Rolando Paciello; Gennaro Riccio; Carmela Coppola; Melina Coppola; Paolo Laccetti; Nicola Maurea; Ronald T Raines; Claudia De Lorenzo
Journal:  Protein Eng Des Sel       Date:  2014-01-12       Impact factor: 1.650

5.  Construction of a human antibody domain (VH) library.

Authors:  Weizao Chen; Zhongyu Zhu; Xiaodong Xiao; Dimiter S Dimitrov
Journal:  Methods Mol Biol       Date:  2009

6.  A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

Authors:  John E Weldon; Laiman Xiang; Oleg Chertov; Inger Margulies; Robert J Kreitman; David J FitzGerald; Ira Pastan
Journal:  Blood       Date:  2008-11-06       Impact factor: 25.476

7.  The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.

Authors:  Seiji Kawa; Masanori Onda; Mitchell Ho; Robert J Kreitman; Tapan K Bera; Ira Pastan
Journal:  MAbs       Date:  2011-09-01       Impact factor: 6.440

Review 8.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

9.  Polyclonal rabbit anti-murine plasmacytoma cell globulins induce myeloma cells apoptosis and inhibit tumour growth in mice.

Authors:  Bo Mu; Jin-liang Yang; Lan-tu Gou; Yu-qin Yao; Yan Zhou; Zhi-hui Cheng; Hua-shan Shi; Zhi-yong Li; Yuan Wen; Fei Leng; Feng-yu Cui; Tian-Tai Ma; Yu-quan Wei
Journal:  Apoptosis       Date:  2011-04       Impact factor: 4.677

Review 10.  Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy.

Authors:  Shan-Shan Qi; Jia-Hui Sun; Hao-Han Yu; Shu-Qin Yu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.